Samsung Biologics Expands ADC Collaboration with LigaChem Biosciences

• Samsung Biologics has extended its collaboration with LigaChem Biosciences to support antibody-drug conjugate (ADC) programs.

• The partnership will utilise Samsung Biologics’ new dedicated ADC facility to enhance the development of ADC therapies for solid tumor treatments.

Samsung Biologics has announced an expanded collaboration with LigaChem Biosciences to provide antibody-drug conjugate (ADC) services. This partnership, which builds on their previous work in ADC programs for solid tumors, will involve Samsung Biologics supporting LigaChem’s ADC pipeline at a newly developed ADC facility.

The facility, a segregated suite with a 500-liter reactor, is equipped to handle the development and manufacture of ADC therapies. Samsung Biologics will use its expertise in large-scale antibody manufacturing and process engineering to support all stages of ADC development, from late discovery through to conjugation.

John Rim, CEO of Samsung Biologics, emphasised the company’s commitment to delivering high-quality therapeutics. He noted that the collaboration would strengthen their capabilities in ADC development, aligning with their goal to meet client timelines while ensuring quality. Similarly, LigaChem’s President and CEO, Yong-Zu Kim, highlighted that the collaboration would enhance the companies’ competitiveness in the global ADC market.

Samsung Biologics is also making strategic investments in ADC linker technologies and protein engineering through its Samsung Life Science Fund, supporting the advancement of this innovative treatment area.